SDRC members use antibodies to enable blood stem cell transplants with minimized side effects

Written By Diana L Sung

Dr. Agnieszka Czechowicz and colleagues used antibody treatment in a phase 1 clinical trial to enable blood-forming stem cell transplantation, an outcome that could pave the way for new islet replacement strategies in diabetes.

Diana L Sung
Previous

SDRC Leadership contribute to recent NIDDK Advisory Council Report
Next

Stanford Study Links Post-Meal Blood Sugar Spikes to Metabolic Health Subtypes